Keryx Biopharmaceuticals (KERX) Receives Notification Of PDUFA Date Extension For Zerenex™
5/23/2014 10:10:16 AM
NEW YORK, May 22, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced today that the U.S. Food and Drug Administration (FDA) has extended the initial Prescription Drug User Fee Act (PDUFA) goal date for its review of the Company's New Drug Application (NDA) seeking marketing approval of ZerenexTM (ferric citrate) by three months. The new PDUFA goal date is September 7, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by